The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study

What Was Tested

The paper reports a study of Argireline (Acetyl Hexapeptide-3/8), published as a randomized controlled trial.

In the objective evaluation, silicone replicas of the skin at the application area were made before and after the treatment, which were analyzed by a wrinkle-analysis apparatus.

Who Took Part

The abstract describes 60 subjects taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A total of 60 subjects received a randomized treatment of argireline or placebo in a ratio of 3:1.

In the subjective evaluation, Daniell's classification and Seeman's standard were applied to make a global assessment of changes in the appearance of peri-orbital lines.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Argireline (Acetyl Hexapeptide-3/8) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the subjects and researchers unaware of who received Argireline (Acetyl Hexapeptide-3/8).

A placebo (an inactive look-alike) gave the Argireline (Acetyl Hexapeptide-3/8) group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Administration, Topical, China, Esthetics, Oligopeptides, Patient Satisfaction and Skin Aging.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Argireline (Acetyl Hexapeptide-3/8) in 60 subjects.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (American journal of clinical dermatology), a journal based in New Zealand.

More context: the Argireline (Acetyl Hexapeptide-3/8) compound page, all human trials.